Incidence and risk factors for gallstones in patients with inflammatory bowel disease: A large case‐control study

Fabrizio Parente, Luca Pastore, Stefano Bargiggia, Claudia Cucino, Salvatore Greco, Mirko Molteni, Sandro Ardizzone, Gabriele Bianchi Porro, Gianluca M. Sampietro, Riccardo Giorgi, Roberto Moretti, Silvano Gallus – 26 April 2007 – The risk for gallstones (GD) in inflammatory bowel diseases and the factors responsible for this complication have not been well established. We studied the incidence of GD in a cohort of Crohn's disease (CD) and ulcerative colitis (UC) patients and investigated the related risk factors. A case‐controlled study was carried out.

Hepatocyte‐specific Gclc deletion leads to rapid onset of steatosis with mitochondrial injury and liver failure

Ying Chen, Yi Yang, Marian L. Miller, Dongxiao Shen, Howard G. Shertzer, Keith F. Stringer, Bin Wang, Scott N. Schneider, Daniel W. Nebert, Timothy P. Dalton – 26 April 2007 – Oxidative stress is considered to be a critical mediator in liver injury of various etiologies. Depletion of glutathione (GSH), the major antioxidant in liver, has been associated with numerous liver diseases.

Liver stiffness measurement predicts severe portal hypertension in patients with HCV‐related cirrhosis

Francesco Vizzutti, Umberto Arena, Roberto G. Romanelli, Luigi Rega, Marco Foschi, Stefano Colagrande, Antonio Petrarca, Stefania Moscarella, Giacomo Belli, Anna Linda Zignego, Fabio Marra, Giacomo Laffi, Massimo Pinzani – 26 April 2007 – Measurement of hepatic venous pressure gradient (HVPG) is a standard method for the assessment of portal pressure and correlates with the occurrence of its complications. Liver stiffness measurement (LSM) has been proposed as a noninvasive technique for the prediction of the complications of cirrhosis.

Racial disparities in the management of hospitalized patients with cirrhosis and complications of portal hypertension: A national study

Geoffrey C. Nguyen, Dorry L. Segev, Paul J. Thuluvath – 26 April 2007 – Having complications of portal hypertension is a harbinger of decompensated cirrhosis and warrants consideration for liver transplantation (LT). Racial disparities in LT have been reported. We sought to characterize disparities in the performing of surgical and endoscopic procedures among hospitalized patients with complications of portal hypertension. We queried the Nationwide Inpatient Sample from 1998 to 2003 to identify patients with cirrhosis and complications of portal hypertension.

Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine

Tsuyoshi Hatakeyama, Chiemi Noguchi, Nobuhiko Hiraga, Nami Mori, Masataka Tsuge, Michio Imamura, Shoichi Takahashi, Yoshiiku Kawakami, Yoshifumi Fujimoto, Hidenori Ochi, Hiromi Abe, Toshiro Maekawa, Hiroiku Kawakami, Hiromi Yatsuji, Yasuyuki Aisaka, Hiroshi Kohno, Shiomi Aimitsu, Kazuaki Chayama – 26 April 2007 – Lamivudine (LAM) is a nucleoside analogue widely used for the treatment of chronic hepatitis B virus (HBV) infection.

Subscribe to